Kura Oncology, Inc. (KURA): Cash & Equivalents
$149.10M
As of 2025-12-31
$70.24M
As of 2026-06-30
+42.2%
3-year compound annual growth
-14.5%
5-year compound annual growth
+25.5%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $149.10M | -33.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $224.46M | +501.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $37.32M | -28.0% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $51.80M | -42.9% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $90.67M | -72.1% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $325.49M | n/m | 2023-02-23, Balance as of period end |
| 2019-12-31 | $26.14M | +62.1% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $16.12M | +41.0% | 2021-02-24, Balance as of period end |
| 2017-12-31 | $11.43M | +17.6% | 2019-03-05, Balance as of period end |
| 2016-12-31 | $9.72M | -37.0% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $15.44M | n/m | 2017-03-14, Balance as of period end |
| 2014-12-31 | $1.12M | n/m | 2016-03-17, Balance as of period end |
| 2013-12-31 | $6.6K | +36.8% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $4.8K | +13.8% | 2015-02-27, Balance as of period end |
| 2011-12-31 | $4.2K | -84.3% | 2014-03-31, Balance as of period end |
| 2010-12-31 | $26.9K | +141.4% | 2013-03-28, Balance as of period end |
| 2009-12-31 | $11.1K | n/a | 2012-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $58.45M | +52.4% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $628.11M | -28.6% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
Compare KURA, SPRO, RMTI, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗